144 related articles for article (PubMed ID: 8045977)
1. Metabolic and behavioral effects of high-dose, exogenous testosterone in healthy men.
Bagatell CJ; Heiman JR; Matsumoto AM; Rivier JE; Bremner WJ
J Clin Endocrinol Metab; 1994 Aug; 79(2):561-7. PubMed ID: 8045977
[TBL] [Abstract][Full Text] [Related]
2. Physiological levels of estradiol stimulate plasma high density lipoprotein2 cholesterol levels in normal men.
Bagatell CJ; Knopp RH; Rivier JE; Bremner WJ
J Clin Endocrinol Metab; 1994 Apr; 78(4):855-61. PubMed ID: 8157711
[TBL] [Abstract][Full Text] [Related]
3. A lower dosage levonorgestrel and testosterone combination effectively suppresses spermatogenesis and circulating gonadotropin levels with fewer metabolic effects than higher dosage combinations.
Anawalt BD; Bebb RA; Bremner WJ; Matsumoto AM
J Androl; 1999; 20(3):407-14. PubMed ID: 10386821
[TBL] [Abstract][Full Text] [Related]
4. Combined administration of levonorgestrel and testosterone induces more rapid and effective suppression of spermatogenesis than testosterone alone: a promising male contraceptive approach.
Bebb RA; Anawalt BD; Christensen RB; Paulsen CA; Bremner WJ; Matsumoto AM
J Clin Endocrinol Metab; 1996 Feb; 81(2):757-62. PubMed ID: 8636300
[TBL] [Abstract][Full Text] [Related]
5. Effects of chronic testosterone administration in normal men: safety and efficacy of high dosage testosterone and parallel dose-dependent suppression of luteinizing hormone, follicle-stimulating hormone, and sperm production.
Matsumoto AM
J Clin Endocrinol Metab; 1990 Jan; 70(1):282-7. PubMed ID: 2104626
[TBL] [Abstract][Full Text] [Related]
6. Establishing the minimum effective dose and additive effects of depot progestin in suppression of human spermatogenesis by a testosterone depot.
Handelsman DJ; Conway AJ; Howe CJ; Turner L; Mackey MA
J Clin Endocrinol Metab; 1996 Nov; 81(11):4113-21. PubMed ID: 8923869
[TBL] [Abstract][Full Text] [Related]
7. Induction of azoospermia in normal men with combined Nal-Glu gonadotropin-releasing hormone antagonist and testosterone enanthate.
Tom L; Bhasin S; Salameh W; Steiner B; Peterson M; Sokol RZ; Rivier J; Vale W; Swerdloff RS
J Clin Endocrinol Metab; 1992 Aug; 75(2):476-83. PubMed ID: 1639948
[TBL] [Abstract][Full Text] [Related]
8. Effects of endogenous testosterone and estradiol on sexual behavior in normal young men.
Bagatell CJ; Heiman JR; Rivier JE; Bremner WJ
J Clin Endocrinol Metab; 1994 Mar; 78(3):711-6. PubMed ID: 8126146
[TBL] [Abstract][Full Text] [Related]
9. Comparison between testosterone enanthate-induced azoospermia and oligozoospermia in a male contraceptive study. III. Higher 5 alpha-reductase activity in oligozoospermic men administered supraphysiological doses of testosterone.
Anderson RA; Wallace AM; Wu FC
J Clin Endocrinol Metab; 1996 Mar; 81(3):902-8. PubMed ID: 8772548
[TBL] [Abstract][Full Text] [Related]
10. A two-year clinical study of the effects of two triphasic oral contraceptives on plasma lipids.
Kakis G; Powell M; Marshall A; Woutersz TB; Steiner G
Int J Fertil Menopausal Stud; 1994; 39(5):283-91. PubMed ID: 7820162
[TBL] [Abstract][Full Text] [Related]
11. The effects of exogenous testosterone on sexuality and mood of normal men.
Anderson RA; Bancroft J; Wu FC
J Clin Endocrinol Metab; 1992 Dec; 75(6):1503-7. PubMed ID: 1464655
[TBL] [Abstract][Full Text] [Related]
12. Effect of testosterone enanthate on serum lipoproteins in man.
Anderson RA; Wallace EM; Wu FC
Contraception; 1995 Aug; 52(2):115-9. PubMed ID: 8536448
[TBL] [Abstract][Full Text] [Related]
13. Impact on lipoprotein profile after long-term testosterone replacement in hypogonadal men.
Berg G; Schreier L; Geloso G; Otero P; Nagelberg A; Levalle O
Horm Metab Res; 2002 Feb; 34(2):87-92. PubMed ID: 11972293
[TBL] [Abstract][Full Text] [Related]
14. Levonorgestrel implants (Norplant II) for male contraception clinical trials: combination with transdermal and injectable testosterone.
Gonzalo IT; Swerdloff RS; Nelson AL; Clevenger B; Garcia R; Berman N; Wang C
J Clin Endocrinol Metab; 2002 Aug; 87(8):3562-72. PubMed ID: 12161475
[TBL] [Abstract][Full Text] [Related]
15. Comparison of a gonadotropin releasing-hormone antagonist plus testosterone (T) versus T alone as potential male contraceptive regimens.
Bagatell CJ; Matsumoto AM; Christensen RB; Rivier JE; Bremner WJ
J Clin Endocrinol Metab; 1993 Aug; 77(2):427-32. PubMed ID: 8345047
[TBL] [Abstract][Full Text] [Related]
16. Comparison between testosterone enanthate-induced azoospermia and oligozoospermia in a male contraceptive study. I: Plasma luteinizing hormone, follicle stimulating hormone, testosterone, estradiol, and inhibin concentrations.
Wallace EM; Gow SM; Wu FC
J Clin Endocrinol Metab; 1993 Jul; 77(1):290-3. PubMed ID: 8325955
[TBL] [Abstract][Full Text] [Related]
17. Effects of long-term use of testosterone enanthate. II. Effects on lipids, high and low density lipoprotein cholesterol and liver function parameters.
Tyagi A; Rajalakshmi M; Jeyaraj DA; Sharma RS; Bajaj JS
Int J Androl; 1999 Dec; 22(6):347-55. PubMed ID: 10624603
[TBL] [Abstract][Full Text] [Related]
18. Testosterone enanthate at a dose of 200 mg/week decreases HDL-cholesterol levels in healthy men.
Meriggiola MC; Marcovina S; Paulsen CA; Bremner WJ
Int J Androl; 1995 Oct; 18(5):237-42. PubMed ID: 8567093
[TBL] [Abstract][Full Text] [Related]
19. Interrelationships among lipoprotein levels, sex hormones, anthropometric parameters, and age in hypogonadal men treated for 1 year with a permeation-enhanced testosterone transdermal system.
Dobs AS; Bachorik PS; Arver S; Meikle AW; Sanders SW; Caramelli KE; Mazer NA
J Clin Endocrinol Metab; 2001 Mar; 86(3):1026-33. PubMed ID: 11238481
[TBL] [Abstract][Full Text] [Related]
20. Suppression of human spermatogenesis by testosterone implants.
Handelsman DJ; Conway AJ; Boylan LM
J Clin Endocrinol Metab; 1992 Nov; 75(5):1326-32. PubMed ID: 1430094
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
